PERFILA FARMACOLÓGICO DA OPICAPONA EM PACIENTES COM DOENÇA DE PARKINSON SOB TRATAMENTO COM LEVODOPA

Abstract

Parkinson’s disease (PD) is a progressive, neurodegenerative disease, characterized by rigidity, tremor, bradykinesia and postural instability, secondary to dopaminergic deficit in the nigrostriatal system. Opicapone is indicated as an adjunctive therapy to combination of LD/DOPA decarboxylase inhibitors (DDCIs) in adult PD patients with motor fluctuations whose symptoms cannot be stabilized with these preparations. Opicapone is a novel catechol-O-methyl transferase (COMT) inhibitor that significantly decreased its activity, increased systemic exposure to levodopa and improved motor response of patient. We aimed to review the pharmacological properties of opicapone, presente preclinical and clinical trials and discuss its potential role in the treatment of PD. CONCLUSIONS: opicapone is indicated to patients on levodopa therapy with motor fluctuations signals. Opicapone dose indicated is 50mg, once a day, at night, 1h after or before levodopa.